The Amicus Therapeutics Inc. (FOLD) Position Boosted by State Board of Administration of Florida Retirement System

The Amicus Therapeutics Inc. (FOLD) Position Boosted by State Board of Administration of Florida Retirement System

State Board of Administration of Florida Retirement System raised its position in shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) by 36.6% during the second quarter, Holdings Channel reports. The firm owned 55,248 shares of the biopharmaceutical company’s stock after buying an additional 14,810 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Amicus Therapeutics were worth $302,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Wexford Capital LP purchased a new stake in shares of Amicus Therapeutics during the first quarter valued at approximately $1,095,000. Bank of New York Mellon Corp boosted its stake in shares of Amicus Therapeutics by 19.8% in the second quarter. Bank of New York Mellon Corp now owns 649,235 shares of the biopharmaceutical company’s stock valued at $3,545,000 after buying an additional 107,215 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its stake in shares of Amicus Therapeutics by 14.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 709,900 shares of the biopharmaceutical company’s stock valued at $3,876,000 after buying an additional 90,000 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Amicus Therapeutics by 1.6% in the first quarter. BlackRock Fund Advisors now owns 5,444,399 shares of the biopharmaceutical company’s stock valued at $46,005,000 after buying an additional 83,654 shares during the last quarter. Finally, GW&K Investment Management LLC boosted its stake in shares of Amicus Therapeutics by 12.3% in the second quarter. GW&K Investment Management LLC now owns 468,708 shares of the biopharmaceutical company’s stock valued at $2,559,000 after buying an additional 51,273 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Amicus Therapeutics Inc. (NASDAQ:FOLD) traded down 3.05% on Friday, hitting $7.00. The company’s stock had a trading volume of 397,807 shares. Amicus Therapeutics Inc. has a 1-year low of $4.98 and a 1-year high of $11.78. The company’s market capitalization is $994.97 million. The company has a 50 day moving average price of $7.26 and a 200-day moving average price of $6.94.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. On average, equities analysts forecast that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current fiscal year.

Several equities research analysts recently commented on FOLD shares. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a report on Monday, July 25th. Chardan Capital set a $15.00 target price on Amicus Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $12.19.

In other news, insider Jay Barth sold 10,458 shares of the stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $7.00, for a total transaction of $73,206.00. Following the sale, the insider now directly owns 15,000 shares of the company’s stock, valued at $105,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William D. Baird III sold 20,500 shares of the stock in a transaction that occurred on Tuesday, September 20th. The shares were sold at an average price of $8.00, for a total transaction of $164,000.00. Following the sale, the chief financial officer now directly owns 56,450 shares in the company, valued at $451,600. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Related posts

Leave a Comment